The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …
Read More »GLP-1s and Pancreatic Cancer: Reassessing Long-Term Safety Signals
Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …
Read More »GLP-1s and Atrial Fibrillation: What Do the Data Suggest?
The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …
Read More »Nutrition Equity in Diabetes: Addressing Food Insecurity Without the Paperwork
Diabetes management often begins with nutrition advice. However, what happens when patients cannot afford fresh produce or live miles from a grocery store? For many people living with diabetes, food insecurity is a growing yet underrecognized barrier to glycemic control. While clinicians routinely discuss carbohydrate counting and meal planning, they …
Read More »Bringing CGM Into the Primary Care Visit: Practical Integration for Non-Specialists
Continuous glucose monitoring was once reserved for endocrinology clinics. Today, integrating CGM into primary care is essential as guidelines recommend earlier and broader use in both type 1 and type 2 diabetes. Yet many clinicians still feel unsure about how to interpret reports or fit CGM into a busy visit. …
Read More »Post-Discharge Diabetes Care: Preventing Lapses in the First 30 Days
Hospital discharge should mark a fresh start. However, for many patients, the period after a diabetes hospital discharge becomes a danger zone. The days following a hospital discharge for diabetes are often marked by hypoglycemia, medication confusion, and missed follow-up visits. In fact, the first 30 days often determine whether …
Read More »Navigating Oral GLP-1s: When to Choose Pills Over Injections
Oral GLP-1 therapy is quickly reshaping how we treat type 2 diabetes, especially for patients who hesitate at the thought of injections. For years, glucagon-like peptide-1 receptor agonists were only available as injectables such as semaglutide and dulaglutide. However, the introduction of semaglutide tablets and the development of higher-dose oral …
Read More »GLP‑1s and Racial/Ethnic Disparities: How Response and Access May Vary
GLP-1 receptor agonists have transformed type 2 diabetes care, improving glycemic control, supporting weight loss, and reducing cardiovascular risk. However, disparities in GLP-1 use and access are becoming harder to ignore. Why do some patients gain access quickly while others face barriers at every step? Data suggest that prescribing patterns …
Read More »GLP-1s and Reproductive Health: What to Know About Fertility, Pregnancy, and PCOS
GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …
Read More »Managing GLP-1 GI Side Effects Before Stopping Therapy
GLP-1 receptor agonists have transformed type 2 diabetes care. Yet for many patients, gastrointestinal side effects from GLP-1 therapy, such as nausea, vomiting, and constipation, can threaten long-term adherence. Have you ever had a patient achieve an impressive A1C reduction but consider stopping therapy because of persistent nausea? You are …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.